Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization

Sponsor
Beni-Suef University
Study ID
NCT07323329
Phase
PHASE2/PHASE3
Status
Recruiting

Conditions

  • Infertility
  • Infertility (IVF Patients)

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 35 Years
Healthy Volunteers
Not accepted

Interventions

  • Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day. — DRUG
    Patients will receive Somatropin (4IU for 1 month)1 S.C injection every 3 days for at least 1 month plus, folic acid 400 mcg per day.
  • DHEA plus folic acid 400mcg per day — DRUG
    Patients will receive DHEA 50 mg twice per day for 12 weeks plus folic acid 400mcg per day
  • control group — DIETARY_SUPPLEMENT
    Patients will receive folic acid 400 mcg per day

Study Details

The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder. The main question it aims to answer is: Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.

Key Dates

First listed
Jan 7, 2026
Start date
Oct 10, 2025
Status verified
Dec 2025
Primary completion
Oct 15, 2026
Completion
Nov 12, 2026

Study Design

Enrollment
165 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Somatropin group
    Somatropin (4IU for 1 month) 1 S.C injection every 3 days for at least 1 month plus, folic acid 400mcg/day
  • Experimental: dehydroepiandrosterone
    dehydroepiandrosterone 50 mg twice per day for 12 weeks plus folic acid 400mcg per day
  • Active Comparator: Standard care
    Patients will receive standard care will receive folic acid 400 mcg per day

Primary Outcome Measure

The number of mature oocyte [ Time Frame: 12 weeks ]

Related Studies